|
1.
|
|
15 p, 2.7 MB |
ALPL-1 is a target for chimeric antigen receptor therapy in osteosarcoma
/
Mensali, Nadia (Department of Cellular Therapy. Oslo University Hospital) ;
Köksal, Hakan (Oslo University Hospital) ;
Joaquina, Sandy (Oslo University Hospital) ;
Wernhoff, Patrick (Oslo University Hospital) ;
Casey, Nicholas P. (Oslo University Hospital) ;
Romecín, Paola Alejandra (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Panisello, Carla (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Rodríguez, René (Instituto de Salud Carlos III) ;
Vimeux, Lene (Université de Paris) ;
Juzeniene, Asta (Oslo University Hospital) ;
Myhre, Marit R. (Oslo University Hospital) ;
Fåne, Anne (Oslo University Hospital) ;
Castilla-Ramirez, Carolina (Virgen del Rocio University Hospital) ;
Maggadottir, Solrun Melkork (Oslo University Hospital) ;
Duru, Adil Doganay (Nova Southeastern University) ;
Georgoudaki, Anna-Maria (Department of Oncology-Pathology. Karolinska Institutet) ;
Grad, Iwona (Oslo University Hospital) ;
Maturana, Andrés Daniel (Nagoya University) ;
Gaudernack, Gustav (Department of Cancer Immunology. Oslo University Hospital) ;
Kvalheim, Gunnar (Department of Cellular Therapy. Oslo University Hospital) ;
Carcaboso, Angel M. (Institut de Recerca Sant Joan de Déu) ;
De Álava, Enrique (Universidad de Sevilla) ;
Donnadieu, Emma (Université de Paris) ;
Bruland, Øyvind S (University of Oslo) ;
Menendez, Pablo (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Inderberg, Else Marit (Oslo University Hospital) ;
Wälchli, Sébastien (Oslo University Hospital)
Osteosarcoma (OS) remains a dismal malignancy in children and young adults, with poor outcome for metastatic and recurrent disease. Immunotherapies in OS are not as promising as in some other cancer types due to intra-tumor heterogeneity and considerable off-target expression of the potentially targetable proteins. [...]
2023 -  10.1038/s41467-023-39097-x
Nature communications, Vol. 14 Núm. 1 (december 2023) , p. 3375
|
|
|
2.
|
|
16 p, 3.5 MB |
Biomarkers Found in the Tumor Interstitial Fluid may Help Explain the Differential Behavior Among Keratinocyte Carcinomas
/
Matas-Nadal, Clara (Hospital de Santa Caterina (Salt, Girona)) ;
Bech-Serra, Joan-Josep (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Gatius, Sònia (Hospital Universitari Arnau de Vilanova) ;
Gomez, Xavier (Universitat de Lleida. Departament de Ciències Mèdiques Bàsiques) ;
Ribes-Santolaria, Marina (Universitat de Lleida. Departament de Ciències Mèdiques Bàsiques) ;
Guasch-Vallés, Marta (Universitat de Lleida. Departament de Ciències Mèdiques Bàsiques) ;
Pedraza, Neus (Universitat de Lleida. Departament de Ciències Mèdiques Bàsiques) ;
Casanova, Josep M. (Hospital Universitari Arnau de Vilanova) ;
De La Torre Gómez, Gisela Carolina (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Gari, Eloi (Universitat de Lleida. Departament de Ciències Mèdiques Bàsiques) ;
Aguayo-Ortiz, Rafael S. (Hospital Universitari Arnau de Vilanova)
Basal cell carcinomas (BCCs) and cutaneous squamous cell carcinomas (SCCs) are the most frequent types of cancer, and both originate from the keratinocyte transformation, giving rise to the group of tumors called keratinocyte carcinomas (KCs). [...]
2023 - 10.1016/j.mcpro.2023.100547
Molecular and Cellular Proteomics, Vol. 22 Núm. 6 (june 2023) , p. 100547
|
|
|
3.
|
|
22 p, 2.9 MB |
Advancing CART therapy for acute myeloid leukemia : recent breakthroughs and strategies for future development
/
Pérez-Amill, Lorena (Department of Immunology. Centre de Diagnòstic Biomèdic (CDB). Hospital Clínic de Barcelona) ;
Bataller, Alex (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Delgado, Julio (Universitat de Barcelona) ;
Esteve, Jordi (Universitat de Barcelona) ;
Juan, Manel (Hospital Sant Joan de Déu (Barcelona, Catalunya)) ;
Klein-González, Nelia (Hospital Clínic i Provincial de Barcelona)
Chimeric antigen receptor (CAR) T therapies are being developed for acute myeloid leukemia (AML) on the basis of the results obtained for other haematological malignancies and the need of new treatments for relapsed and refractory AML. [...]
2023 - 10.3389/fimmu.2023.1260470
Frontiers in immunology, Vol. 14 (2023) , p. 1260470
|
|
|
4.
|
|
16 p, 3.4 MB |
CAR-Ts redirected against the Thomsen-Friedenreich antigen CD176 mediate specific elimination of malignant cells from leukemia and solid tumors
/
Dragon, Anna Christina (Hannover Medical School) ;
Beermann, Luca Marie (Hannover Medical School) ;
Umland, Melina (Hannover Medical School) ;
Bonifacius, Agnes (Hannover Medical School) ;
Malinconico, Chiara (Hannover Medical School) ;
Ruhl, Louisa (Hannover Medical School) ;
Kehler, Patrik (Glycotope GmbH) ;
Gellert, Johanna (Glycotope GmbH) ;
Weiß, Lisa (Glycotope GmbH) ;
Mayer-Hain, Sarah (Glycotope GmbH) ;
Zimmermann, Katharina (Hannover Medical School) ;
Riese, Sebastian (Hannover Medical School) ;
Thol, F. (Department of Hematology. Hannover Medical School) ;
Beutel, Gernot (Hannover Medical School) ;
Maecker-Kolhoff, B. (Department of Pediatric Hematology and Oncology. Hannover Medical School) ;
Yamamoto, Felicitas (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Blasczyk, Rainer (Hannover Medical School) ;
Schambach, Axel (Hannover Medical School) ;
Hust, Michael (Department of Medical Biotechnology. Technical University of Braunschweig) ;
Hudecek, Michael (Department of Internal Medicine II. University Hospital of Würzburg) ;
Eiz-Vesper, Britta (Hannover Medical School) ;
Universitat Autònoma de Barcelona
Introduction: Chimeric antigen receptor-engineered T cells (CAR-Ts) are investigated in various clinical trials for the treatment of cancer entities beyond hematologic malignancies. A major hurdle is the identification of a target antigen with high expression on the tumor but no expression on healthy cells, since "on-target/off-tumor" cytotoxicity is usually intolerable. [...]
2023 - 10.3389/fimmu.2023.1219165
Frontiers in immunology, Vol. 14 (2023) , p. 1219165
|
|
|
5.
|
|
20 p, 1.1 MB |
RHOA Therapeutic Targeting in Hematological Cancers
/
Santos, Juliana (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Profitós-Pelejà, Núria (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Sánchez Vinces, Salvador (Sao Francisco University Medical School, São Paulo, Brazil) ;
Roué, Gaël (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras)
Primarily identified as an important regulator of cytoskeletal dynamics, the small GTPase Ras homolog gene family member A (RHOA) has been implicated in the transduction of signals regulating a broad range of cellular functions such as cell survival, migration, adhesion and proliferation. [...]
2023 - 10.3390/cells12030433
Cells, Vol. 12 Núm. 3 (february 2023) , p. 433
|
|
|
6.
|
|
13 p, 3.0 MB |
Defining the optimal sequence for the systemic treatment of metastatic breast cancer
/
Albanell Mestres, Joan (Hospital del Mar (Barcelona, Catalunya)) ;
Barnadas i Molins, Agustí (Institut d'Investigació Biomèdica Sant Pau) ;
Martínez, Leticia C. (Complejo Hospitalario Universitario de A Coruña) ;
López-Muñiz, José Ignacio Chacón (Hospital Virgen de la Salud (Toledo)) ;
Ciruelos, Eva (Hospital 12 de Octubre (Madrid)) ;
de Juan Ferre, Ana (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria)) ;
del Barco Berrón, S. (Institut Català d'Oncologia) ;
Pérez, Y.F. (Hospital Universitario Central de Asturias) ;
Mata, J.G. (Hospital Santa María Nai en Ourense) ;
Palomo, A.G. (Complejo Asistencial de León) ;
Gregori, J.G. (Fundació Institut Valencià d'Oncologia) ;
Pardo, P.G. (Hospital Universitari Vall d'Hebron) ;
Mañas, J.J.I. (Complejo Hospitalario de Navarra) ;
Hernández, A.L. (Hospital Clínic Universitari (València)) ;
de Dueñas, E.M. (Consorci Hospitalari Provincial de Castelló) ;
Jáñez, N.M. (Hospital Universitario Ramón y Cajal (Madrid)) ;
Murillo, S.M. (Hospital Universitari Arnau de Vilanova) ;
Bofill, J.S. (Hospital Universitario Nuestra Señora de Valme) ;
Auñón, P.Z. (Hospital Universitario La Paz (Madrid)) ;
Sanchez-Rovira, P. (Complejo Hospitalario de Jaén) ;
Universitat Autònoma de Barcelona
Metastatic breast cancer is a heterogeneous disease that presents in varying forms, and a growing number of therapeutic options makes it difficult to determine the best choice in each particular situation. [...]
2017 - 10.1007/s12094-016-1520-2
Clinical & Translational Oncology, Vol. 19 Núm. 2 (january 2017) , p. 149-161
|
|
|
7.
|
|
17 p, 2.0 MB |
Differences and similarities in endothelial and angiogenic profiles of preeclampsia and COVID-19 in pregnancy
/
Palomo, Marta (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Youssef, Lina (BCNatal (Hospital Clínic and Hospital Sant Joan de Déu)) ;
Ramos, Alex (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Torramade-Moix, Sergi (Hospital Clínic i Provincial de Barcelona) ;
Moreno-Castaño, Ana Belén (Hospital Clínic i Provincial de Barcelona) ;
Martinez-Sanchez, Julia (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Bonastre, Laura (Hospital Clínic i Provincial de Barcelona) ;
Pino, Marc (Hospital Clínic i Provincial de Barcelona) ;
Gomez-Ramirez, Pilar (Hospital Clínic i Provincial de Barcelona) ;
Martin, Lidia (Hospital Clínic i Provincial de Barcelona) ;
Garcia Mateos, Estefania (Hospital Clínic i Provincial de Barcelona) ;
Sanchez, Pablo (Institut de Ciències del Mar) ;
Fernandez, Sara (Hospital Clínic i Provincial de Barcelona) ;
Crovetto, Francesca (Hospital Clínic i Provincial de Barcelona) ;
Escolar, Ginés (Hospital Clínic i Provincial de Barcelona) ;
Carreras, Enric (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Castro Rebollo, Pedro (Universitat de Barcelona) ;
Gratacos, Eduard (Hospital Clínic i Provincial de Barcelona) ;
Crispi, Fatima (Hospital Clínic i Provincial de Barcelona) ;
Diaz-Ricart, Maribel (Hospital Clínic i Provincial de Barcelona)
Background: COVID-19 presents a spectrum of signs and symptoms in pregnant women that might resemble preeclampsia. Differentiation between severe COVID-19 and preeclampsia is difficult in some cases. [...]
2022 - 10.1016/j.ajog.2022.03.048
American Journal of Obstetrics and Gynecology, Vol. 227 Núm. 2 (august 2022)
|
|
|
8.
|
|
21 p, 9.8 MB |
Stroma-derived HGF drives metabolic adaptation of colorectal cancer to angiogenesis inhibitors
/
Mira, Alessia (Candiolo Cancer Institute) ;
Morello, Virginia (University of Torino Medical School) ;
Céspedes, María Virtudes (Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina) ;
Perera, Timothy (OCTIMET Oncology Ltd) ;
Comoglio, Paolo M. (Candiolo Cancer Institute) ;
Mangues, Ramon 1957- (Institut d'Investigació Biomèdica Sant Pau) ;
Michieli, Paolo (University of Torino Medical School) ;
Universitat Autònoma de Barcelona
The role of paracrine Hepatocyte Growth Factor (HGF) in the resistance to angiogenesis inhibitors (AIs) is hidden in xenograft models because mouse HGF fails to fully activate human MET. To uncover it, we compared the efficacy of AIs in wild-type and human HGF knock-in SCID mice bearing orthotopic human colorectal tumors. [...]
2017 - 10.18632/oncotarget.16942
Oncotarget, Vol. 8 Núm. 24 (2017) , p. 38193-38213
|
|
|
9.
|
|
34 p, 1.3 MB |
Inhibitors of aldehyde dehydrogenases of the 1A subfamily as putative anticancer agents : Kinetic characterization and effect on human cancer cells
/
Jiménez, Rafael (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ;
Pequerul, Raquel (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ;
Amor Minguez, Adrián (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ;
Lorenzo Rivera, Julia (Universitat Autònoma de Barcelona. Institut de Biotecnologia i de Biomedicina "Vicent Villar Palasí") ;
Metwally, Kamel (Zagazig University. Department of Medicinal Chemistry) ;
Avilés, Francesc X (Universitat Autònoma de Barcelona. Institut de Biotecnologia i de Biomedicina "Vicent Villar Palasí") ;
Parés i Casasampera, Xavier (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ;
Farrés, Jaume (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular)
Aldehyde dehydrogenases (ALDHs) are enzymes catalyzing the NAD(P)+-dependent oxidation of aldehydes to their corresponding carboxylic acids. High ALDH activity has been related to some important features of cancer stem cells. [...]
2019 - 10.1016/j.cbi.2019.04.004
Chemico-Biological Interactions, Vol. 306 (2019) , p. 123-130
|
|
|
10.
|
|
11 p, 1.1 MB |
Considerations on diagnosis and surveillance measures of PTEN hamartoma tumor syndrome : clinical and genetic study in a series of Spanish patients
/
Pena-Couso, Laura (Centro Nacional de Investigaciones Oncológicas Carlos III (Espanya). Familial Cancer Clinical Unit) ;
Ercibengoa Arana, Maria (Respiratory Infection and Antimicrobial Resistance Group. Infectious Diseases Area. BioDonostia; Microbiology Department. Osakidetza Basque Health Service. Donostialdea Integrated Health Organization) ;
Mercadillo, Fátima (Familial Cancer Clinical Unit. Spanish National Cancer Research Centre (CNIO)) ;
Gómez-Sánchez, David (Clinical and Translational Lung Cancer Research Unit. i+12 Research Institute and Biomedical Research Networking Center in Oncology (CIBERONC)) ;
Inglada-Pérez, Lucia (Biostatistics Unit. Statistics and Operational Research Department. Faculty of Medicine. Complutense University of Madrid) ;
Santos, Maria Lucia S.F. (Hereditary Endocrine Cancer Group. Spanish National Cancer Research Centre (CNIO)) ;
Lanillos, Javier (Hereditary Endocrine Cancer Group. Spanish National Cancer Research Centre (CNIO)) ;
Gutiérrez-Abad, David (Medical Oncology Service. University Hospital of Fuenlabrada) ;
Hernández, Almudena (Dermatology Service. University Hospital of Fuenlabrada) ;
Carbonell, Pablo (Biochemistry and Clinical Genetics Centre. Virgen Arrixaca University Hospital) ;
Letón, Rocío (Hereditary Endocrine Cancer Group. Spanish National Cancer Research Centre (CNIO)) ;
Robledo, Mercedes (Centro de Investigación Biomédica en Red de Enfermedades Raras) ;
Rodriguez-Antona, Cristina (Centro de Investigación Biomédica en Red de Enfermedades Raras) ;
Perea García, José (Health Research Institute-Fundación Jiménez Díaz University Hospital) ;
Urioste, Miguel (Familial Cancer Clinical Unit. Spanish National Cancer Research Centre (CNIO)) ;
Alonso, Miguel Ángel (Virgen del Camino Hospital) ;
Andrés, Raquel (0000-0002-0762-6415) ;
Arévalo, Sara (Hospital of Donostia) ;
Arias, Maria del Mar (Virgen del Camino Hospital) ;
Balmaña Gelpí, Judith (Hospital Universitari Vall d'Hebron) ;
Beristain, Elena (Txagorritxu Hospital) ;
Blanco Guillermo, Ignacio (Institut Català d'Oncologia) ;
Boronat, Mauro (Hospital of Gran Canaria) ;
Brunet, Joan (Institut Català d'Oncologia) ;
Cózar-León, Victoria (Hospital Universitario Virgen de Valme (Sevilla, Andalusia)) ;
del Campo Casanelles, Miguel (Hospital Universitari Vall d'Hebron) ;
Díaz, Arantza (Móstoles Hospital) ;
Gabau, Elisabeth (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Barcina, María Jesús (Hospital de Basurto (Bilbao, Biscaia)) ;
González, Margarita (Can Misses Hospital) ;
Guitart, Miriam (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Hernán, Imma (Terrassa Hospital) ;
Hernández, Héctor Salvador (Sant Joan de Déu Hospital) ;
Hernando, Susana (Alcorcón Hospital) ;
Lacambra, Carmen (Severo Ochoa Hospital) ;
Lasa, Adriana (Institut d'Investigació Biomèdica Sant Pau) ;
Lastra, Enrique (Hospital of Burgos) ;
Llort, Gemma (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
del Rosario Marín, Maria (Puerta del Mar Hospital) ;
Marrupe, David (Móstoles Hospital) ;
Martínez, Francisco (Hospital Universitario Nuestra Señora de Candelaria (Santa Cruz de Tenerife)) ;
Martínez, Victor (La Paz Hospital) ;
Martorell, Loreto (Sant Joan de Déu Hospital) ;
Orera, Maria (Gregorio Marañón Hospital) ;
Pedrinaci, Susana (Hospital Universitario Virgen de las Nieves (Granada)) ;
Pérez, Pedro (San Carlos Hospital) ;
Pineda, Marta (Institut Català d'Oncologia) ;
Plasencia, Ana Maria (Asturias Central Hospital) ;
Ramon y Cajal, Teresa (Institut d'Investigació Biomèdica Sant Pau) ;
Robles, Luis ;
Rodà, Diana (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Rodríguez, Nuria (La Paz Hospital) ;
Rosell Andreo, Jordi (Son Dureta Hospital) ;
Sáez, Raquel (Hospital of Donostia) ;
Salvat, Monica (Sant Joan de Reus) ;
Sánchez, Antonio (Hospital Universitario Puerta de Hierro Majadahonda (Madrid)) ;
Santana, Alfredo (Hospital of Gran Canaria) ;
Soto, Jose Luis (General Hospital of Elche) ;
Toll, Agustin (Del Mar Hospital) ;
Tuneu, Anna (Hospital of Donostia) ;
Vázquez, Carlos (Hospital of Gran Canaria)
Background: The limited knowledge about the PTEN hamartoma tumor syndrome (PHTS) makes its diagnosis a challenging task. We aimed to define the clinical and genetic characteristics of this syndrome in the Spanish population and to identify new genes potentially associated with the disease. [...]
2022 - 10.1186/s13023-021-02079-7
Orphanet Journal of Rare Diseases, Vol. 17 Núm. 1 (december 2022) , p. 85
|
|
guest ::
email alert
or subscribe to the 
RSS feed.
